Amgen EVP reports tax withholding of 499 shares
Amgen Inc. executive Jonathan P. Graham reported a small tax-related share disposition.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Amgen Inc. executive Jonathan P. Graham reported a small tax-related share disposition. On the transaction date, 499 shares of Amgen common stock were withheld at $331.11 per share to cover exercise price or tax liability, a routine administrative event rather than an open-market sale.
After this tax-withholding disposition, Graham directly held 39,712 Amgen shares. His holdings include 311 Dividend Equivalents granted under Amgen’s equity incentive plan, which are tied to unvested Restricted Stock Units and pay out in shares on a one-to-one basis as those awards vest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 499 | $331.11 | $165K |
Footnotes (1)
- F1. These shares include 311 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Key Figures
Key Terms
Dividend Equivalents financial
Restricted Stock Units financial
Equity Incentive Plan financial
tax-withholding disposition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Amgen (AMGN) report for Jonathan P. Graham?
What are Dividend Equivalents mentioned in Jonathan P. Graham’s Amgen (AMGN) filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.